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INTRODUCTION
Asthma is an important chronic airway disease worldwide,
and its prevalence is increasing in all regions including Korea
(1). The goal of asthma management, according to the GINA
guidelines, is to achieve optimum disease control (2). How-
ever, because of the multifaceted nature of asthma, different
measures such as clinical assessment (symptoms and quality
of life), functional parameters (spirometry), and biomarkers
of inflammation are used to evaluate asthma control. 
Several questionnaires have been developed to measure
asthma control, such as, the Asthma Control Test (ACTTM;
ACT is a trademark of QualiMetric, Lincoln RI) (3), the
Asthma Control Questionnaire (ACQ) (4), the Asthma Ther-
apy Assessment Questionnaire (ATAQ) (5), and the Asthma
Control Scoring System (ACSS) (6). These tools have been
validated for various applications, including use by health
care providers to assess the state of control of asthma and by
patients for self-assessment purposes as part of a written per-
sonal asthma action plan. These tests have the potential to
improve assessments of asthma control and provide repro-
ducible objective measures that can be charted over time (2).
It has been assumed that if an objective clinical measure
improves that a patient’s symptoms and quality of life must
also improve. However, asthma may affect health-related
quality of life (HRQL) in ways that objective clinical mea-
sures cannot predict, and they may be unable to fully assess
whether a patient feels or functions better (physically, social-
ly, and emotionally) in everyday life (7, 8). Moreover, it is
difficult to establish a clear correlation between objective
and subjective parameters, as they appear to measure partic-
ular aspects of the disease and to be partially independent.
This has been demonstrated by poor correlations between
symptoms and lung function (4, 9, 10), or quality of life (7).
We considered that the ACT may directly correlate with
HRQL because it includes questions on symptoms, daily
activities, and uniquely, a self-assessment of asthma control,
which may all affect HRQL. However, the correlation between
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Correlation between the Korean Version of Asthma Control Test and
Health-Related Quality of Life in Adult Asthmatics
The Asthma Control Test (ACT) is a patient-completed questionnaire developed to
assess asthma control. Health-related quality of life (HRQL) in asthmatics has shown
relatively low correlations with parameters of asthma control and the relationship
between the ACT and HRQL in asthmatics is yet unclear. Because revalidations
of translated versions of questionnaires are critical for its utilization, we first sought
to validate the Korean version of ACT and then to evaluate the relationship between
the ACT and HRQL. Patients (n=117) completed the ACT and asthma-related quality
of life questionnaire (AQLQ) at 3 physician visits. Pulmonary function was measured
and an asthma specialist rated asthma control. The Korean version of ACT was
found to be reliable, valid, and responsive to changes in asthma control over time
up to three consecutive visits. ACT scores correlated significantly (p=0.001) with
symptoms domain (r=0.72), activity domain (r=0.65), emotional domain (r=0.69),
and environmental domain (r=0.67) of AQLQ. In conclusion, the Korean version of
the ACT was found to be a reliable and valid tool for measuring asthma control,
and to correlate well with AQLQ scores. Moreover, the ACT was responsive to
changes in AQLQ scores over time.
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the ACT and HRQL in asthmatics is still unclear. 
Because the translation of questionnaires into other lan-
guages and their utilizations in different cultural backgrounds
may affect results, revalidations of translated versions of ques-
tionnaires are critical (11, 12). The aims of this study were
to validate the Korean version of the ACT and to evaluate
its relationship with HRQL.
MATERIALS AND METHODS
Study design
We conducted a longitudinal study in an adult outpatient
population at our Asthma and Allergy Clinic. At each of
the three clinic visits, separated by 4 to 12 weeks, spirome-
try was conducted and the self-administered ACT and asth-
ma-related quality-of-life questionnaire (AQLQ) were com-
pleted. Ratings of asthma severity were done as previously
described (3, 13). However, the ‘‘completely controlled’’ cat-
egory was omitted because differentiating ‘‘completely con-
trolled’’ from ‘‘well controlled’’ was not at issue in the pre-
sent study. Asthma specialists blinded to the results of ACT
and AQLQ surveys rated asthma control on a 4-point scale:
1) ‘‘not controlled at all’’; 2) ‘‘poorly controlled’’; 3) ‘‘some-
what controlled’’; and 4) ‘‘well controlled’’. Specialists were
instructed to base their ratings on how well the GINA-defin-
ed goals of asthma were being met (14), as determined on
the basis of patient history, a physical examination, and FEV1
measurement. 
No accepted system of defining control in relation to these
goals has been articulated during the study period, which
started before the revised version of GINA guidelines with
3 control categories was published in late 2006. In the absence
of specific criteria, we believed that the best approach was
to use the summary judgment of experienced specialists
aware of both the GINA goals of therapy and all relevant
aspects of patient clinical status. Moreover, to maintain the
same design as the original study, we decided to allow the
well experienced asthma specialist to assess asthma control
without specific written criteria (3, 13).
The study protocol was approved by the institutional review
board of Seoul National University Bundang Hospital.
Subjects
From January 2006 through December 2006, 117 subjects
under the care of an asthma specialist were recruited from
among outpatients visiting the Asthma and Allergy Clinic
of Seoul National University Bundang Hospital. Patients
15 yr of age or older were eligible if they had; 1) current physi-
cian-diagnosed asthma (diagnosed within the previous 3 yr)
without other respiratory comorbidities, 2) documented evi-
dence of β 2-agonist reversibility of forced expiratory volume
in one second (FEV1) of more than both 20% and 200 mL
(15), 3) had normal chest radiograph, 4) were literate in Kore-
an, and 5) not participating in other clinical studies at the
time of enrollment. Patients and parents or guardians, or
both, provided written informed consent. 
Asthma control test
The ACT, a patient-completed questionnaire, contains 5
questions, which require responses on a 1 to 5 scale, where
higher scores reflecting better asthma control. The ACT
assesses the effect of asthma on daily functioning, daytime
asthma symptoms (shortness of breath), nocturnal symp-
toms, use of rescue medications, and self assessment of asth-
ma control. Thus, the higher total response scores to the 5
questions (range 5 to 25) correspond to better control. In
the original ACT survey study, ACT scores of 19 or less have
been associated with uncontrolled asthma and scores of 15
or less have been associated with poorly controlled or uncon-
trolled asthma (3, 13). 
The use of the Korean version of ACT survey was permit-
ted by QualiMetric Incorporated, U.S.A. (16).
Health-Related quality of life measures
The asthma-related quality-of-life was evaluated using
the Korean modification of the Juniper asthma quality-of-
life questionnaire (AQLQ), named Quality of Life Question-
naire in Adult Korean Asthmatics, which has been previ-
ously described (8, 17, 18). Answers to each question were
scored on a 5-point scale, with a score of 1 representing great-
est impairment and a score of 5 representing no impairment.
Items were weighted equally and are reported as mean scores
for each domain (activity limitations, emotions, symptoms,
and exposure to environmental stimuli) along with the over-
all mean score.
Spirometry
Spirometry was performed using a SensorMedics 2130
(SensorMedics Corporation, CA, U.S.A.). Forced vital capac-
ity (FVC) and forced expiratory volume at one second (FEV1)
were recorded according to ATS recommendations (19). The
higher of two values for FEV1 (reproducible within 100 mL)
was recorded and percentages of predicted FEV1 values were
calculated (20). 
Statistical analysis
To assess the measurement properties of the Korean ver-
sion of the ACT, the following aspects were analyzed: 1) inter-
nal consistency reliability; 2) test-retest reliability; 3) crite-
rion validity; and 4) discriminant validity. 
Cronbach’s α -coefficient values were estimated from ACTAsthma Control Test and Asthma-Related Quality of Life 623
item responses at baseline and follow-up visits. This coeffi-
cient was calculated based on the mean correlation of each
item in the scale with the sum total of the scale, and on the
total number of items (21). Test-retest reliabilities were assess-
ed by calculating intraclass correlations between ACT scores
during the three clinic visits. Test-retest reliability analysis
was limited to a subset of patients whose asthma control
was stable, as determined by the same specialist’s ratings of
asthma control at both baseline and follow-up visits.
Criterion validities of the Korean version of ACT survey
were evaluated by computing correlations between ACT
scores and specialist’s assessments of asthma control and
between ACT scores and percentage of predicted FEV1 val-
ues at baseline visits.
Discriminant validity of the ACT was also evaluated based
on clinical tests using the known-group validity method and
data from baseline visits. In this study, 3 such measures were
used. The first was the asthma specialist’s rating of asthma
control, which consisted of the 4 categories mentioned above,
and the second measure consisted of percent predicted FEV1
values. Patients were categorized into 4 groups based on their
percent predicted FEV1 values, i.e., 1) less than 60%; 2) 60%
to 79%; 3) 80% to 99%; and 4) greater than 100%. This
stratification of percent predicted FEV1 values was roughly
based on the FEV1 values mentioned in the four levels of
asthma severity in the GINA guidelines (14). The third mea-
sure consisted of the asthma specialist’s prescription of oral
corticosteroids for asthma exacerbation. This was used to
categorize patients into 2 groups: 1) the group with oral cor-
ticosteroid rescue and 2) the group without oral corticos-
teroid rescue. For each of the above measures, mean ACT
scores were computed and compared across patient groups.
One-way ANOVA was used to test the significances of dif-
ferences between mean ACT scores across groups of patients
who differed in terms of specialist ratings of asthma control,
percent predicted FEV1 values, and oral corticosteroid pre-
scriptions. 
The responsiveness of ACT scores was evaluated using
Pearson’s correlation and ANOVA. First, changes in ACT
scores from baseline to follow-up visits were correlated with
changes in the specialist’s rating of asthma control and changes
in lung function as measured by the change in FEV1 values.
Second, ANOVA was used to compare mean changes in
ACT scores across groups of patients who differed in terms
of changes in the specialist’s rating of asthma control and
changes in percent predicted FEV1 values. 
Changes in specialist control ratings were derived by sim-
ply subtracting baseline ratings from follow-up ratings; these
rating involved 4 levels, as mentioned above. Patients were
grouped into 5 categories of control rating changes: 1) a poor-
er rating by two or more levels; 2) a poorer rating by one
level; 3) the same rating; 4) an improved rating by one level;
and 5) an improved rating by two levels. 
Changes in percent predicted FEV1 values were derived
by subtracting baseline percent predicted FEV1 values from
follow-up percent predicted FEV1 values and then dividing
by the baseline percent predicted FEV1 value. Patients were
categorized into 3 groups based on the stratification method
used in the original study (3, 13), where a 10% change in
percent predicted FEV1 value from baseline was considered
clinically significant: 1) improved by 10% or more from
baseline; 2) improved by less than 10% from baseline; and
3) decreased versus baseline.
Correlations between changes in the ACT and AQLQ
scores were evaluated at each visit. Mean ACT scores were
compared in different AQLQ groups. We categorized the
subjects into 4 groups by dividing the 5-point scale: 1) 1 to
1.9; 2) 2 to 2.0; 3) 3 to 3.9; 4) 4 to 5. When using 7-point
scale response options in the original Juniper’s Asthma Quali-
ty of Life Questionnaire, a within subject change in score of
0.5 represents the minimal important difference in quality
of life and advocates that score change of 0.5 is generalizable
to all areas of health-related quality of life in assessing mini-
mal important change (22). Because our modified AQLQ
uses 5-point scale response, although it has not been validat-
ed, it can be assumed that score lesser than 0.5 could repre-
sent minimal important change in quality of life. Thus, the
groups differing in mean AQLQ score of 1, which is twice
the score of minimal important change mentioned above,
should represent groups differing in quality of life. Addition-
ally, changes in mean ACT scores were evaluated in groups
of patients differing in changes in AQLQ scores of 0.5 mea-
sured at each visit. 
Concurrent validity between the ACT and AQLQ was
examined using Pearson’s correlation coefficients (r) for rele-
vant domains in order to compare the questionnaires. Valid-
ity measurements were performed using ACT scores and
scores of the activity, symptoms, emotions, and environment
domains of the AQLQ. A correlation coefficient of greater
than 0.8 indicates an excellent correlation, between 0.5 and
0.8 a moderate correlation, between 0.3 and 0.5 a weak cor-
relation, and of less than 0.3 a lack of correlation (23). Vari-
ables were analyzed using SPSS 12.0 for Windows.
RESULTS 
Sample 
A total of 117 patients participated in this study and these
patients made 272 visits. Of the 117 patients, 102 patients
visited the office twice and 53 patients visited three times.
Patients enrolled early in the study were able to make up to
3 visits and patients enrolled toward the end of the study
period made 2 visits (Table 1). There was a wide range of
ages among the subjects from minimum age of 15 to maxi-
mum age of 87. More than two thirds of the asthmatic sub-
jects were well controlled. The lowest percent predicted FEV1624 H.-S. Kwon, S.-H. Lee, M.-S. Yang, et al.
value was 27% and the highest percent predicted FEV1 value
was 143%.
Reliability of the ACT
The internal consistency reliability of the ACT survey, as
determined by Cronbach’s α -coefficient, was 0.71 at base-
line visits (n=117) and the test-retest reliability among the
61 subjects who had the same specialist ratings for asthma
control over two visits, had an intraclass correlation coeffi-
cient (ICC) of 0.83 (n=61) between baseline and second vis-
its. To determine whether ACT is reliable for multiple con-
secutive visits, it was calculated in 19 patients, who had the
same specialist asthma control rating for three consecutive
visits. The test-retest reliability shown by ICC in these 19
patients was 0.72, between baseline and second visits, 0.70
between second and third visits, and 0.74 between baseline
and third visits (Fig. 1).
Criterion validity of the ACT
Statistically significant correlations were observed between
ACT scores and specialist’s ratings of asthma control at base-
line visits (r=0.87, p=0.001). However, ACT scores were
not correlated with baseline percent predicted FEV1 values
(r=0.28, p=0.004).
Discriminant validity of the ACT
Significant differences in mean scores across groups of
patients who differed in terms of clinical measures related
to asthma control may reflect the discriminant validity of
the ACT scores (Table 2). Mean ACT scores were signifi-
cantly lower among patients with poorer control, as judged
by the specialist, than among patients with more favorable
control ratings (p=0.001). Likewise, patients prescribed oral
glucocorticoid rescue treatment scored significantly lower
on the ACT than patients not prescribed this treatment (p=
0.001). However, no differences in mean ACT scores were
observed among patients with different percentages of pre-
dicted FEV1 values (p=0.126). 
Responsiveness of the ACT
The responsiveness of ACT scores to changes in asthma
control were evident from correlations between changes in
ACT scores and changes in specialist control ratings or changes
in percentage predicted FEV1 values. Changes in the ACT
scores were found to be correlated significantly with changes
in control levels as assessed by the specialist at second visits
(r=0.81, p=0.001) and at third visits (r=0.80, p=0.001).
Changes in ACT scores correlated weakly with changes in
percent predicted FEV1 values measured at second visits
(r=0.43, p=0.001) and at third visits (r=0.31, p=0.022).
The responsiveness of the ACT was also demonstrated by
*Asthma specialists rated asthma control on a 4-point scale based on
how well the GINA-defined goals of asthma were met as determined
based on patient history, physical examination, and FEV1 measure-
ments. This rating method was based on the original study of the ACT
survey (3, 13).
FEV1, forced expiratory volume in one second.
Baseline visit Second visit Third visit
n 117 102 53
Sex, M:F 49:51 49:51 47:53
Mean age, yr (SD) 52.7 (15.4) 53.1 (15.3) 54.2 (15.3)
Age categories, n (%)
Younger than 20 yr 2 (1.7) 1 (1.0) 0
20 to 39 yr 26 (22.2) 23 (22.5) 11 (20.8)
40 to 59 yr 40 (34.2) 34 (33.3) 19 (35.8)
60 to 79 yr 47 (40.2) 42 (41.2) 21 (39.6)
Older than 80 yr 2 (1.7) 2 (2.0) 2 (3.8)
Status of asthma control, n (%)*
Well controlled 68 (58.1) 71 (69.6) 36 (67.9)
Somewhat controlled 30 (25.6) 16 (15.7) 12 (22.6)
Poorly controlled 15 (12.8) 12 (11.8) 5 (9.4)
Not controlled at all 4 (3.4) 3 (2.9)
Percent predicted FEV1 categories, n (%)
More than 100% 35 (29.9) 29 (28.7) 19 (35.8)
80 to 100% 43 (36.8) 44 (43.6) 19 (35.8)
60 to 79% 30 (25.6) 21 (20.8) 11 (20.8)
Less than 60% 9 (7.7) 7 (6.9) 4 (7.5)
Mean % predicted FEV1,  88.4 (18.5) 88.2 (18.6) 89.8 (19.7)
% (SD)
Table 1. Sample characteristics 
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Fig. 1. Test-retest reliability of the Asthma Control Test in 19 patients
with the same control rating levels at 3 consecutive visits. Intra-
class correlation coefficients (ICC) were evaluated between base-
line and second visits, second and third visits, and between base-
line and third visits.Asthma Control Test and Asthma-Related Quality of Life 625
evaluating mean changes in ACT scores across groups of
patients who differed in level of change according to the spe-
cialist’s rating of asthma control and percent predicted FEV1
values (Table 3). Mean changes in ACT scores differed signif-
icantly across groups of patients differing in level of change
according to the specialist’s control ratings measured at sec-
ond and third visits (p=0.001). Mean changes in ACT scores
differed in groups of patients with different changes in per-
cent predicted FEV1 values at second visits (p=0.023) and
third visits (p=0.035). 
Relationship between the ACT and AQLQ
To evaluate the concurrent validity of the ACT versus the
AQLQ, correlations between ACT and each of the four do-
mains of AQLQ were evaluated over all total visits (Table
4). ACT scores correlated significantly with the symptoms
domain (r=0.72, p=0.001), the activity domain (r=0.65, p=
0.001), the emotional domain (r=0.69, p=0.001), and the
environmental domain (r=0.67, p=0.001) on the AQLQ.
Total AQLQ scores also correlated with total ACT scores
(r=0.69, p=0.001).
Statistically significant correlations were observed between
ACT scores and AQLQ scores at baseline visits (r=0.70, p=
0.001). Mean ACT scores were significantly lower for patients
with lower AQLQ scores than for patients with higher AQLQ
scores (p=0.001) (Table 2). Changes in ACT and AQLQ scores
correlated with each other at second (r=0.62, p=0.001) and
at third visits (r=0.64, p=0.016). Changes in mean ACT
scores differed significantly in groups of patients differing
in changes in AQLQ scores measured at second visits (p=
0.001) and at third visits (p=0.049) (Table 3).
*This stratification of percentage of predicted FEV1 values was roughly
based on the FEV1 values mentioned in the four steps of asthma severi-
ty in the GINA guidelines (2); 
� This stratification method of AQLQ scores
was done simply by dividing the 5-scale point scores into 4 groups.
Although this stratification method has not been validated, it was based
on the fact that change in score of 0.5 in 7-point scale represents mini-
mal important change of quality of life (22) and that score difference of
1 which is twice the score of minimal important change mentioned above
would stratify groups differing in quality of life.
FEV1, forced expiratory volume in one second; AQLQ, asthma quality
of life questionnaire.
N Mean (SD)
F 
statistics
p 
value
Specialist assessment 133.7 <0.001
Well controlled 68 22.9 (1.4)
Somewhat controlled 30 18.3 (2.3)
Poorly controlled 15 14.5 (2.1)
Uncontrolled 4 13.0 (1.4)
Percent predicted FEV1 (%)* 5.9 0.126
More than 100% 35 21.1 (3.3)
80% to 100% 43 19.9 (4.0)
60% to 79% 30 19.6 (3.7)
Less than 60% 9 18.6 (4.3)
Oral glucocorticoid rescue 22.5 0.001
No 100 20.8 (3.7)
Yes 17 17.5 (3.2)
Mean AQLQ scores
� 30.1 <0.001
4 to 5 65 22.2 (2.6)
3 to 3.9 45 18.3 (3.8)
2 to 2.9 7 15.4 (2.0)
1 to 1.9 0 0
Table 2. Discriminant validity tests on mean ACT scores at base-
line visits (n=117)
Baseline → Second visit (n=102)
N Mean (SD) F statistics (p value)
Second → Third visit (n=53)
N Mean (SD) F statistics (p value)
Specialist assessment* F=138.0 (p=0.001) F=58.1 (p=0.001)
Better by two rating levels 7 7.6 (1.6) 1 6.0 (0)
Better by one rating level 20 4.9 (1.8) 9 3.6 (2.4)
Same 61 0.3 (1.3) 31 -0.3 (1.3)
Worse by one rating level 11 -4.4 (1.8) 9 -4.2 (2.2)
Worse by two rating levels 3 -9.0 (2.6) 3 -4.3 (2.1)
FEV1
� F=30.9 (p=0.023) F=30.6 (p=0.035)
Increased by more than 10% 14 2.9 (4.1) 5 1.2 (1.3)
Increased by 0 to 10% 38 1.5 (2.8) 22 0.6 (2.7)
Decreased 50 0.0 (4.1) 26 -1.5 (3.4)
AQLQ scores F=30.1 (p=0.001) F=20.8 (p=0.049)
Increased by more than 0.5 27 3.7 (3.7) 6 0.5 (3.1)
Increased by 0 to 0.5 39 1.2 (2.6) 27 0.3 (3.2)
Decreased by 0 to 0.5 30 -1.2 (2.9) 16 -1.6 (2.3)
Decreased by more than 0.5 6 -4.2 (5.8) 4 -3.3 (2.6)
Table 3. Mean changes in ACT scores in different groups of patients
*Differences in asthma control level on a 4-point scale assessed by the asthma specialist; 
� Stratified based on the method previously reported where
a 10% change in percentage predicted FEV1 from baseline was considered clinically significant (3, 13).
FEV1, forced expiratory volume in one second; AQLQ, asthma quality of life questionnaire.626 H.-S. Kwon, S.-H. Lee, M.-S. Yang, et al.
DISCUSSION
The results of this study demonstrated that the Korean
version of ACT is reliable, valid, and responsive to changes
in asthma control over time in a sample of Korean asthmat-
ic outpatients under the care of an asthma specialist. Based
on this tool, we found that the ACT correlates significantly
with the AQLQ and with each of the four specific domains
(activity, emotions, symptoms, and environment) in the
AQLQ.
Because the translation of questionnaires into other lan-
guages and different cultural backgrounds may affect the
results of questionnaires, and in order to facilitate interna-
tional multicentric studies, cross-cultural adaptation and
revalidation of each translated version of a questionnaire are
crucial for its utilization (11, 12). We successfully validated
the officially translated version of the Korean ACT, which is
available on a public website (16). Thus, this study indicates
that the Korean version of ACT is as valid and reliable as the
original, and that it can be used in international multi-cen-
ter studies.
There is no universal gold standard for asthma control
measurement because of its multifaceted nature. Thus, as
was done during the original study (3, 13), we decided to
use an experienced asthma specialist’s assessment of asthma
control based on the GINA goals of asthma control as the
‘‘gold standard’’ (3). Although there are no specific criteria
for assessing asthma control, as is stated in the newly revised
version of GINA guidelines (2), we considered that the best
approach was to use the summary judgment of experienced
specialists, who were aware of both the GINA goals of ther-
apy and all relevant aspects of patient clinical status. We also
used AQLQ, a valid and reproducible tool to assess quality
of life in Korean asthma patients (17, 18), to allow compar-
isons of ACT scores with the multidimensional effects of
asthma on daily life. 
The original ACT survey was evaluated over two clinic
visits (3, 13). In our study, we deepened the value of the lon-
gitudinal study by evaluating test-retest reliability, discrim-
inant validity, and responsiveness to changes in asthma con-
trol over 3 consecutive clinic visits. Test-retest reliability of
19 patients with same control rating levels at 3 consecutive
visits showed a consistent value of intraclass correlation coef-
ficient, indicating that the Korean version of the ACT is
reproducible over serial applications in stable adult asthma
patients. It has been shown that assessments of short-term
symptom burdens underestimate the long-term functional
burden of asthma (24). Thus, the long-term functional effect
of the disease is best captured by serial applications of a stan-
dard questionnaire over time (25), and the present study
shows that ACT may be useful in such serial applications. 
In the present study, we correlated ACT scores and AQLQ
scores. Concurrent validity was evaluated by demonstrating
that each domain of the AQLQ is significantly correlated
with total ACT scores. ACT scores were found to consistently
correlate well with AQLQ scores over multiple visits with
highest correlation in symptoms domain and showed good
discriminant validity in terms of assessing different levels
asthma-related quality of life (Table 2). Moreover, the ACT
was found to be responsive to changes in asthma-related qual-
ity of life over time. 
No correlations were found between ACT scores and FEV1
values or between AQLQ scores and FEV1 values. Because
the ACT and the AQLQ ask to what extent asthma has been
like over several weeks, measurement of lung function at a
single time may not correlate well with either ACT or AQLQ
scores. This observation concurs with those made in other
studies, where either no significant correlation or a relative-
ly low correlation was found between asthma symptoms and
FEV1 (4, 9, 10). However, changes in ACT scores were found
to correlate weakly with changes in percent predicted FEV1
values, and mean changes in ACT scores differed in groups
of patients with different changes in percentage predicted
FEV1 values at different visits. These results suggested that
changes in lung function over time may have a more impor-
tant clinical values than lung function value per se in terms
of assessing asthma control.
In summary, this is the first validation study of the Kore-
an version of the ACT survey. The Korean version of ACT
was found to provide an objective assessment of asthma con-
trol, and to be reliable, valid, and responsive to changes in
asthma control over time. Moreover, the ACT correlated well
Symptoms 
domain
Activity domain
Emotional
domain
Environment
domain
AQLQ score ACT score
Symptoms domain 0.50 0.64 0.56 0.85 0.72
Activity domain 0.50 0.47 0.41 0.73 0.65
Emotional domain 0.64 0.47 0.55 0.79 0.69
Environment domain 0.56 0.41 0.55 0.74 0.67
AQLQ score 0.85 0.73 0.79 0.74 0.69
ACT score 0.72 0.65 0.69 0.67 0.69
Table 4. Concurrent validity between ACT and AQLQ (n=272)*,�
*n=total visits; 
� p<0.001 for all values shown as Pearson’s correlation coefficients.
AQLQ, asthma quality of life questionnaire; ACT, Asthma Control Test; FEV1, forced expiratory volume in one second.Asthma Control Test and Asthma-Related Quality of Life 627
with AQLQ and was also responsive to changes in AQLQ
over time. Because the ACT reflects multiple dimensions of
quality of life as well as clinical symptoms, it may be the
most useful single measure in busy clinics and clinical stud-
ies, where multiple aspects of asthma control should be con-
sidered in a relatively short time.
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